Efferon at LIVES 2026 in Lisbon!

At the 39th ESICM Annual Congress, Efferon joined clinicians and partners worldwide to discuss how hemoadsorption can go beyond endotoxin in sepsis treatment.

Ivan Bessonov, Efferon’s Co-Founder and CTO, successfully presented the MINERVA study on Efferon LPS in maternal sepsis and septic shock. At our booth, conversations focused on Efferon LPS, Efferon NEO, and the role of hemoadsorption in critical care.

Thank you to everyone who visited us in Lisbon and to European Society of Intensive Care Medicine - ESICM for bringing the intensive care community together.

LIVES 2026 was another opportunity to rethink hemoadsorption in sepsis, share clinical research, and discuss the wider use of Efferon technologies in clinical practice.